2.8.1. Sample size.
pain
GROUP B
Target number of patients is 5 patients in the icatibant-placebo group (Group A), and 5 patients in the placebo-icatibant group (Group B). Considering the minimum number of patients to achieve the study objectives and the rarity of sweating-induced dermal pain, total 10 eligible patients will be enrolled and evaluated in this proof-of-concept study.